Lack of prognostic implications of HER-2/neu abnormalities in 345 Stage I nonsmall cell carcinomas (NSCLC) and 207 Stage I-III neuroendocrine tumours (NET) of the lung

International Journal of Cancer

Volumn 113, Issue 1, 2005, Pages 101-108

  Pelosi, Giuseppe ^a,c   Del Curto, Barbara ^a   Dell'Orto, Patrizia ^a   Pasini, Felice ^b   Veronesi, Giulia ^c   Spaggiari, Lorenzo ^c   Maisonneuve, Patrick ^c   Iannucci, Antonio ^d   Terzi, Alberto ^d   Lonardoni, Alessandro ^d   Viale, Giuseppe ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d City Hospital   (Italy)

Author keywords

Amplification; Early stage; FISH; Gene; HER 2 neu; Neuroendocrine tumours; NSCLC; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NEUROENDOCRINE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; UP-REGULATION;

EID: 8644239447     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20542     Document Type: Article

References (69)

1. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 2002;37:17-27.
2. Lohrisch C, Piccart M. An overview of HER2. Semin Oncol 2001;28:3-11.
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-55.
4. Fajac A, Benard J, Lhomme C. c-erb-B2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis. Int J Cancer 1995;64:146-51.
5. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
7. Meert A-P, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout J-M, Delmotte P, Lafitte J-J, Sculier J-P. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003;89:959-65.
8. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/Neu expression in malignant lung tumors. Semin Oncol 2002;29:51-8.
9. Micke P, Hengstler JG, Ros R, Bittinger F, Metz T, Gebhard S, Beeh KM, Oesch F, Buhl R. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 2001;92:474-9.
10. Potti A, Willardson J, Forseen C, Gantu AK, Koch M, Hebert B, Levitt R, Mehdi SA. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 2002;36:257-61.
11. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Kawasaki N, Kato H. Correlation between encoded protein overexpression and copy number of the Her2 gene with survival in non-small cell lung cancer. Int J Cancer 2003;103:61-6.
12. Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicolo G, Perdelli L, Stampino CG, Rosso R, Puntoni R. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer 2001;92:1896-904.
13. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001;7:1850-5.
14. Cantero R, Torres AJ, Maestro M, Fernandez C, Hernando F, del Barco V, Sanz T, Balibrea JL. Use of possible synergistic expression of p53 and p185 as a prognostic tool for stage I non-small-cell lung cancer. World J Surg 1999;23:1294-9; discussion 99-300.
15. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-43.
16. Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF. Prognostic value of immunohistocheinical expressions of p53. HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002;33:105-10.
17. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-6.
18. Hsieh CC, Chow KC, Fahn HJ, Tsai CM, Li WY, Huang MH, Wang LS. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac Surg 1998;66:1159-64.
19. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-7.
20. Schneider PM, Praeuer HW, Stoeltzing O, Boehm J, Manning J, Metzger R, Fink U, Wegerer S, Hoelscher AH, Roth JA. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer 2000;83:473-9.
21. Selvaggi G, Scagliotti GV, Torri V, Novello S, Leonardo E, Cappia S, Mossetti C, Ardissone F, Lausi P, Borasio P. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 2002;94:2669-74.
22. Tateishi M, Ishida T, Kohdono S, Hamatake M, Fukuyama Y, Sugimachi K. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 1994;3:109-13.
23. Yu CJ, Shun CT, Yang PC, Lee YC, Shew JY, Kuo SH, Luh KT. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer. Am J Respir Crit Care Med 1997;155:1419-27.
24. Shi D, He G, Cao S, Pan W, Zhang HZ, Yu D, Hung MC. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog 1992;5:213-18.
25. Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003;12:201-11.
26. Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, Niewoehner DE. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 1998;157:1093-7.
27. Reinmuth N, Brandt B, Kunze W-P, Junker K, Thomas M, Achatzy R, Scheld HH, Semik M. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000;16:991-6.
28. Carbognani P, Tincani G, Crafa P, Sansebastiano G, Pazzini L, Zoni R, Bobbio A, Rusca M. Biological markers in non-small cell lung cancer: retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg (Torino) 2002;43:545-8.
29. Fu XL, Zhu XZ, Shi DR, Xiu LZ, Wang LJ, Zhao S, Qian H, Lu HF, Xiang YB, Jiang GL. Study of prognostic predictors for non-small cell lung cancer. Lung Cancer 1999;23:143-52.
30. Giatromanolaki A, Koukourakis MI, O'Byrne K, Kaklamanis L, Dicoglou C, Trichia E, Whitehouse R, Harris AL, Gatter KC. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res 1996;16:3819-25.
31. Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, Green MR. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer 1998;21:203-11.
32. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, Zeng C, Baron A, Bunn PA, Jr. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-56.
33. Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, Yang JB. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998;22:181-90.
34. Kwiatkowski DJ, Harpole DH, Jr, Godleski J, Herndon JE, 2nd, Shieh DB, Richards W, Blanco R, Xu HJ, Strauss GM, Sugarbaker DJ. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77.
35. Liao M, Wang H, Lin Z, Feng J, Zhu D. Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer 2001;33:125-32.
36. MacKinnon M, Kerr KM, King G, Kennedy MM, Cockburn JS, Jeffrey RR. p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. Eur J Cardiothorac Surg 1997;11:838-42.
37. Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farre G, Labib T, Pettier G, Sesboue R, Bronner C, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000;6:1125-34.
38. Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, Taylor W, Solano M, Stone M, Mallams J, Mues G. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 1998;21:155-60.
39. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, F Rilke. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
40. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996;74:86-91.
41. Shou Y, Hirano T, Gong Y, Kato Y, Yoshida K, Ohira T, Ikeda N, Konaka C, Ebihara Y, Zhao F, Kato H. Influence of angiogenetic factors and matrix metalloproteinases upon tumor progression in non-small-cell lung cancer. Br J Cancer 2001;85:1706-12.
42. Visscher DW, Yadrandji S, Tabaczka P, Kraut M, Sarkar FH. Clinicopathologic analysis of k-ras, p53, and ERBB-2 gene alterations in pulmonary adenocarcinoma. Diagn Mol Pathol 1997;6:64-69.
43. Volm M, Drings P, Wodrich W, van Kaick G. Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases. Clin Exp Metastasis 1993;11:325-9.
44. Cline MJ, Battifora H. Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. Cancer 1987;60:2669-74.
45. Shiraishi M, Noguchi M, Shimosato Y, Sekiya T. Amplification of protooncogenes in surgical specimens of human lung carcinomas. Cancer Res 1989;49:6474-9.
46. Slebos RJ, Evers SG, Wagenaar SS, Rodenhuis S. Cellular protooncogenes are infrequently amplified in untreated non-small cell lung cancer. Br J Cancer 1989;59:76-80.
47. HER2 expression in human non-small cell lung cancer cell lines. Am J Resp Cell Mol Biol 1992;6:359-63.
48. Schneider PM, Hung MC, Chiocca SM, Manning J, Zhao XY, Fang K, Roth JA. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 1989;49:4868-971.
49. Chiba W, Sawai S, Hanawa T, Ishida H, Matsui T, Kosaba S, Watanabe S, Hatakenaka R, Matsubara Y, Funatsu T. Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected cancer. Gan To Kagaku Ryoho 1993;20:824-7.
50. Pellegrini C, Falleni M, Marched A, Cassani B, Miozzo M, Buttitta F, Roncalli M, Coggi G, Bosari S. HER-2/Neu alterations in non-small cell lung cancer, a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003;9:3645-52.
51. Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, Baron A, Zeng C, Chan DC. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotheraputic agents. Clin Cancer Res 2001;7:3239-50.
52. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A. Protein overexpression and gene amplification of c-erbB-2 in pulmonary carcinomas: a comparative immunohistochemical and florescence in situ hybridization study. Mod Pathol 2001;14:556-62.
53. Harpole DH Jr, Marks JR, Richards WG, Herndon JE, Sugarbaker DJ. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clin Cancer Res 1995;1:659-744.
54. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O'Byrne KJ. Herceptest: Her2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001;92:480-3.
55. Pelosi G, Fraggetta F, Sonzogni A, Fazio N, Cavallon A, Viale G. CD99 immunoreactivity in gastrointestinal and pulmonary neuroendocrine tumours. Virchows Archiv 2000;437:270-4.
56. Hyde L, Yee J, Wilson R. Cell type and the natural history of lung cancer. JAMA 1965;193:52-4.
57. Burry RW. Specificity controls for immunocytochemical methods. J Histochem Cytochem 2000;48:163-6.
58. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 2001;7:1669-75.
59. Heinmöller P, Gross C, Beyser K, Schmidgten C, Maass G, Pedrocchi M, Rüschoff J. HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of Herceptin. Clin Cancer Res 2003;9:5238-44.
60. Fontanini G, Boldrini L, Calcinai A, Chine S, Lucchi M, Mussi A, Angeletti CA, Basolo F, Bevilacqua G. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density. Clin Cancer Res 1999;5:155-61.
61. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A, Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
62. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.
63. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, van de Vijver M. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-82.
64. Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001;14:677-85.
65. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, Perng RP. Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996;56:206-9.
66. Hirsch FR, Franklin WA, Bunn PA Jr. What is the role of HER-2/neu and trastuzumab (HERCEPTIN®) in lung cancer? Lung Cancer 2002;36:263-4.
67. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH, 2598 Eastern Cooperative Oncology Group Study. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004;22:1180-7.
68. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Pritsche HA Jr, Ro JY, Ordonez NG, Tran HT, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004;44:99-110.
69. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27.